This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Neurology	Lysophosphatidic acid receptor 1 (LPAR1; EDG2; LPA1)	<p>A study in mice suggests LPAR1 antagonists may help prevent or treat hemorrhage-associated fetal hydrocephalus (FH). In mouse embryos given lysophosphatidic acid to induce FH, pretreatment with an LPAR1 antagonist decreased disease-associated histological changes in the brain compared with vehicle. Next steps include studying different chemical scaffolds of LPAR1 antagonists and dosing the molecules at different points during FH disease progression.</p> <p>AM152, an LPA1 antagonist from Bristol-Myers Squibb Co., has completed Phase I testing for pulmonary fibrosis.</p> <p>SciBX 4(37); doi:10.1038/scibx.2011.1049 Published online Sept. 22, 2011</p>	Unpatented; licensing status not applicable	<p>Yung, Y.C. <i>et al. Sci. Transl. Med.</i>; published online Sept. 7, 2011; doi:10.1126/scitranslmed.3002095</p> <p>Contact: Jerold Chun, The Scripps Research Institute, La Jolla, Calif. e-mail: jchun@scripps.edu</p>